BRAF and melanoma: More recently it was demonstrated that the addition of the immune checkpoint inhibitor atezolizumab to vemurafenib and cobimetinib can improve the progression free survival of melanoma patients with BRAF V600E mutations (Sullivan et al., 2019; Gutzmer et al., 2020).